BR112022000495A2 - Formulação, comprimido, processo para fabricar o comprimido, e, método para tratar doença cardíaca - Google Patents

Formulação, comprimido, processo para fabricar o comprimido, e, método para tratar doença cardíaca

Info

Publication number
BR112022000495A2
BR112022000495A2 BR112022000495A BR112022000495A BR112022000495A2 BR 112022000495 A2 BR112022000495 A2 BR 112022000495A2 BR 112022000495 A BR112022000495 A BR 112022000495A BR 112022000495 A BR112022000495 A BR 112022000495A BR 112022000495 A2 BR112022000495 A2 BR 112022000495A2
Authority
BR
Brazil
Prior art keywords
tablet
making
formulation
heart disease
treating heart
Prior art date
Application number
BR112022000495A
Other languages
English (en)
Inventor
Chunsheng Qiao
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of BR112022000495A2 publication Critical patent/BR112022000495A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

formulação, comprimido, processo para fabricar o comprimido, e, método para tratar doença cardíaca. são aqui providas formulações compreendendo o inibidor de sarcômero cardíaco (r)-n-(5-(5-etil-1,2,4-oxadiazol-3-il)-2,3-di-hidro-1h-inden-1-il)-1-metil-1h-pirazol-4-carboxamida, processos para fabricar tais formulações e métodos para tratar várias doenças e condições cardíacas com tais formulações.
BR112022000495A 2019-07-17 2020-07-16 Formulação, comprimido, processo para fabricar o comprimido, e, método para tratar doença cardíaca BR112022000495A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962875358P 2019-07-17 2019-07-17
PCT/US2020/042389 WO2021011808A1 (en) 2019-07-17 2020-07-16 Cardiac sarcomere inhibitor oral formulations

Publications (1)

Publication Number Publication Date
BR112022000495A2 true BR112022000495A2 (pt) 2022-03-03

Family

ID=71995104

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022000495A BR112022000495A2 (pt) 2019-07-17 2020-07-16 Formulação, comprimido, processo para fabricar o comprimido, e, método para tratar doença cardíaca

Country Status (20)

Country Link
US (1) US20220265612A1 (pt)
EP (1) EP3999038B1 (pt)
JP (1) JP2022542804A (pt)
KR (1) KR20220082804A (pt)
CN (1) CN114765954B (pt)
AU (1) AU2020315642A1 (pt)
BR (1) BR112022000495A2 (pt)
CA (1) CA3144972A1 (pt)
CL (1) CL2022000108A1 (pt)
DK (1) DK3999038T3 (pt)
FI (1) FI3999038T3 (pt)
HR (1) HRP20240200T1 (pt)
IL (1) IL289884A (pt)
LT (1) LT3999038T (pt)
MX (1) MX2022000708A (pt)
PL (1) PL3999038T3 (pt)
PT (1) PT3999038T (pt)
RS (1) RS65302B1 (pt)
TW (1) TW202116307A (pt)
WO (1) WO2021011808A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11964967B2 (en) 2018-06-26 2024-04-23 Cytokinetics, Inc. Cardiac sarcomere inhibitors
KR20210068422A (ko) 2018-08-31 2021-06-09 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
BR112023017461A2 (pt) 2021-03-04 2023-09-26 Cytokinetics Inc Compostos, composição farmacêutica, métodos de tratamento de doença cardíaca, de uma doença ou afecção associada à cardiomiopatia hipertrófica, de uma doença ou afecção que está associada ao espessamento secundário da parede do ventrículo esquerdo, de uma doença ou afecção associada à pequena cavidade ventricular esquerda e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia miocárdica ou fibrose cardíaca, de uma doença ou afecção selecionada a partir de distrofias musculares e doenças de armazenamento de glicogênio, e, método de inibição do sarcômero cardíaco
EP4370116A1 (en) 2021-07-16 2024-05-22 Cytokinetics, Inc. Methods for treating hypertrophic cardiomyopathy
WO2024020468A1 (en) 2022-07-20 2024-01-25 Cytokinetics, Incorporated Methods for treating non-obstructive hypertrophic cardiomyopathy
US20240115554A1 (en) 2022-08-04 2024-04-11 Cytokinetics, Incorporated Methods for treating obstructive hypertrophic cardiomyopathy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049603A1 (en) * 2005-09-01 2007-03-01 Greg Miknis Raf inhibitor compounds and methods of use thereof
NZ617025A (en) * 2009-09-18 2014-03-28 Sanofi Sa (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4’-trifluormethylphenyl)-amide tablet formulations with improved stability
US9199945B2 (en) * 2013-06-21 2015-12-01 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
US9902702B2 (en) * 2014-07-15 2018-02-27 Bristol-Myers Squibb Company Spirocycloheptanes as inhibitors of rock
DK3356345T3 (da) * 2015-09-30 2024-02-12 Max Planck Gesellschaft Heteroaryl-derivater som sepiapterin-reduktase-inhibitorer
MA51620A (fr) * 2018-01-19 2020-11-25 Cytokinetics Inc Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques

Also Published As

Publication number Publication date
KR20220082804A (ko) 2022-06-17
CA3144972A1 (en) 2021-01-21
PT3999038T (pt) 2024-03-14
MX2022000708A (es) 2022-02-23
RS65302B1 (sr) 2024-04-30
LT3999038T (lt) 2024-03-25
CL2022000108A1 (es) 2022-10-21
JP2022542804A (ja) 2022-10-07
US20220265612A1 (en) 2022-08-25
EP3999038A1 (en) 2022-05-25
WO2021011808A1 (en) 2021-01-21
DK3999038T3 (da) 2024-03-18
FI3999038T3 (fi) 2024-02-21
PL3999038T3 (pl) 2024-05-13
IL289884A (en) 2022-03-01
AU2020315642A1 (en) 2022-03-03
CN114765954B (zh) 2024-01-02
EP3999038B1 (en) 2024-01-10
HRP20240200T1 (hr) 2024-04-26
CN114765954A (zh) 2022-07-19
TW202116307A (zh) 2021-05-01

Similar Documents

Publication Publication Date Title
BR112022000495A2 (pt) Formulação, comprimido, processo para fabricar o comprimido, e, método para tratar doença cardíaca
BR112022000494A2 (pt) Polimorfo, métodos para preparar polimorfo, para tratar doença cardíaca, para tratar uma doença ou condição e para inibir o sarcômero cardíaco, e, composição farmacêutica
BR112022002581A2 (pt) Inibidores heterocíclicos de rip1 quinase
MX2020001328A (es) Muteinas de interleucina 21 y metodos de tratamiento.
BR112017017074A2 (pt) Compostos; sal; bis-tosilatos de n-((s)-5-((1r,2s)-2-(4- fluorofenil)ciclopropilamino)-1-(4-metilpiperazin-1- il)-1-oxopentan-2-il)-4-(1h-1,2,3-triazol-1-il)benzamida; sal de tosilato de um composto; sal de bis- tosilato de um composto; compostos, sais, polimorfos ou solvatos; composições farmacêuticas, método para inibição de kdm1a; métodos para tratamento de uma doença mediada por kdm1a ou globina; método para atingir um efeito em um paciente; método para inibir pelo menos uma função de kdm1a
BR112022007612A2 (pt) Inibidores de raf quinases
AU2017382297A8 (en) Phosphodiesterase inhibitors and methods of microbial treatment
NO20082311L (no) Terapeutisk middel for hjertesykdom
MX2021007001A (es) Moleculas inhibidoras de acido nucleico de cadena doble que contienen un tribucle.
PH12018501356A1 (en) Cocrystal, production method tereof, and medicament containing cocrystal
EA201791021A1 (ru) 1-[2-(АМИНОМЕТИЛ)БЕНЗИЛ]-2-ТИОКСО-1,2,3,5-ТЕТРАГИДРО-4H-ПИРРОЛО[3,2-d]ПИРИМИДИН-4-ОНЫ КАК ИНГИБИТОРЫ МИЕЛОПЕРОКСИДАЗЫ
BR112021026531A2 (pt) Composto, composição farmacêutica, e, método para prevenir ou tratar uma doença mediada pela tirosina cinase 2
BR112021022380A2 (pt) Inibidores de jak
BR112021021477A2 (pt) Composto, composição farmacêutica e método para tratar uma doença mediada por jak em um indivíduo necessitando do mesmo
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
WO2019200314A3 (en) Hinokitiol analogues, methods of preparing and pharmaceutical compositions thereof
PH12018502529A1 (en) Crystalline form of compound suppressing protein kinase activity, and application thereof
BRPI0410951A (pt) nucleotìdeos para prevenção e tratamento de patologias bacterianas e fungicas
EP4293113A3 (en) Expression inhibitor of inflammation promoting factor, screening method for active ingredient thereof, expression cassette useful for said method, diagnostic agent and diagnosis method
Bariteau et al. Biomechanical evaluation of mini-fragment hardware for supination external rotation fractures of the distal fibula
BR112022000523A2 (pt) Polimorfo, métodos para preparar polimorfo, para tratar doença cardíaca, para tratar uma doença ou condição e para inibir o sarcômero cardíaco, e, composição farmacêutica
MX2023005056A (es) Formas cristalinas de un inhibidor de cinasa de desoxicitidina y sus usos.
GB202010984D0 (en) Computer implemented method for assessing the growth of germinative growths from germinative units
WO2020165838A9 (en) Methods for treating ocular surface pain
CN111094272A (zh) 一种otr抑制剂的可药用盐、晶型及制备方法

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]